150 related articles for article (PubMed ID: 34680272)
1. European Multicenter Study on Degradable Starch Microsphere TACE: The Digestible Way to Conquer HCC in Patients with High Tumor Burden.
Ludwig JM; Iezzi R; Theysohn JM; Albrecht T; Posa A; Gross A
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680272
[TBL] [Abstract][Full Text] [Related]
2. DSM-TACE of HCC: Evaluation of Tumor Response in Patients Ineligible for Other Systemic or Loco-Regional Therapies.
Haubold J; Reinboldt MP; Wetter A; Li Y; Ludwig JM; Lange C; Wedemeyer H; Schotten C; Umutlu L; Theysohn J
Rofo; 2020 Sep; 192(9):862-869. PubMed ID: 32131109
[TBL] [Abstract][Full Text] [Related]
3. Degradable starch microspheres transarterial chemoembolization (DSMs-TACE) in patients with unresectable hepatocellular carcinoma (HCC): long-term results from a single-center 137-patient cohort prospective study.
Orlacchio A; Chegai F; Roma S; Merolla S; Bosa A; Francioso S
Radiol Med; 2020 Jan; 125(1):98-106. PubMed ID: 31583558
[TBL] [Abstract][Full Text] [Related]
4. Safety and Efficacy of Degradable Starch Microspheres Transcatheter Arterial Chemoembolization (DSM-TACE) in the Downstaging of Intermediate-Stage Hepatocellular Carcinoma (HCC) in Patients With a Child-Pugh Score of 8-9.
Minici R; Ammendola M; Manti F; Siciliano MA; Minici M; Komaei I; Currò G; Laganà D
Front Pharmacol; 2021; 12():634087. PubMed ID: 33897422
[TBL] [Abstract][Full Text] [Related]
5. TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib.
Iezzi R; Pompili M; Rinninella E; Annicchiarico E; Garcovich M; Cerrito L; Ponziani F; De Gaetano A; Siciliano M; Basso M; Zocco MA; Rapaccini G; Posa A; Carchesio F; Biolato M; Giuliante F; Gasbarrini A; Manfredi R;
Eur Radiol; 2019 Mar; 29(3):1285-1292. PubMed ID: 30171360
[TBL] [Abstract][Full Text] [Related]
6. Trans-arterial chemoembolization with degradable starch microspheres (DSM-TACE) versus selective internal radiation therapy (SIRT) in multifocal hepatocellular carcinoma.
Auer TA; Jonczyk M; Collettini F; Marth A; Wieners G; Hamm B; Gebauer B
Acta Radiol; 2021 Mar; 62(3):313-321. PubMed ID: 32498543
[TBL] [Abstract][Full Text] [Related]
7. Transarterial Chemoembolisation (TACE) with Degradable Starch Microspheres (DSM) and Anthracycline in Patients with Locally Extensive Hepatocellular Carcinoma (HCC): Safety and Efficacy.
Gross A; Albrecht T
Cardiovasc Intervent Radiol; 2020 Mar; 43(3):402-410. PubMed ID: 31705244
[TBL] [Abstract][Full Text] [Related]
8. Transarterial chemoembolization using degradable starch microspheres and iodized oil in the treatment of advanced hepatocellular carcinoma: evaluation of tumor response, toxicity, and survival.
Kirchhoff TD; Bleck JS; Dettmer A; Chavan A; Rosenthal H; Merkesdal S; Frericks B; Zender L; Malek NP; Greten TF; Kubicka S; Manns MP; Galanski M
Hepatobiliary Pancreat Dis Int; 2007 Jun; 6(3):259-66. PubMed ID: 17548248
[TBL] [Abstract][Full Text] [Related]
9. Survival and Outcome in Patients Receiving Drug-Eluting Beads Transarterial Chemoembolization for Large Hepatocellular Carcinoma (>5 cm).
Mukund A; Bhardwaj K; Choudhury A; Sarin SK
J Clin Exp Hepatol; 2021; 11(6):674-681. PubMed ID: 34866846
[TBL] [Abstract][Full Text] [Related]
10. Repeated Transarterial Chemoembolization with Degradable Starch
Microspheres (DSMs-TACE) of Unresectable Hepatocellular Carcinoma: A Prospective Pilot Study.
Orlacchio A; Chegai F; Francioso S; Merolla S; Monti S; Angelico M; Tisone G; Mannelli L
Curr Med Imaging Rev; 2018 Aug; 14(4):637-645. PubMed ID: 30197583
[TBL] [Abstract][Full Text] [Related]
11. Transarterial chemoembolization with degradable starch microspheres (DSM-TACE): an alternative option for advanced HCC patients? Preliminary results.
Iezzi R; Pompili M; Nestola M; Siciliano M; Annicchiarico E; Zocco MA; Rinninella E; Posa A; Antonuccio GE; Gasbarrini A; Bonomo L;
Eur Rev Med Pharmacol Sci; 2016 Jul; 20(13):2872-7. PubMed ID: 27424988
[TBL] [Abstract][Full Text] [Related]
12. Transarterial chemoembolization (TACE) with degradable starch microspheres (DSM) in hepatocellular carcinoma (HCC): multi-center results on safety and efficacy.
Schicho A; Pereira PL; Haimerl M; Niessen C; Michalik K; Beyer LP; Stroszczynski C; Wiggermann P
Oncotarget; 2017 Sep; 8(42):72613-72620. PubMed ID: 29069813
[TBL] [Abstract][Full Text] [Related]
13. Safety and Long-Term Survival Outcome in Patients With Unresectable Barcelona Clinic Liver Cancer (BCLC) Stages C and D Advanced Hepatocellular Carcinoma Treated With 40 μm Drug-Eluting Bead Transcatheter Arterial Chemoembolization.
Wholey M; Palacios Iii R; Wholey D; Mendez A
Cureus; 2022 Apr; 14(4):e24047. PubMed ID: 35573558
[TBL] [Abstract][Full Text] [Related]
14. Transarterial chemoembolization (TACE) using mitomycin and lipiodol with or without degradable starch microspheres for hepatocellular carcinoma: comparative study.
Gruber-Rouh T; Schmitt C; Naguib NNN; Nour-Eldin NA; Eichler K; Beeres M; Vogl TJ
BMC Cancer; 2018 Feb; 18(1):188. PubMed ID: 29444653
[TBL] [Abstract][Full Text] [Related]
15. Transarterial Chemoembolization (TACE) Combined With Sorafenib versus TACE in Patients With BCLC Stage C Hepatocellular Carcinoma - A Retrospective Study.
Patidar Y; Chandel K; Condati NK; Srinivasan SV; Mukund A; Sarin SK
J Clin Exp Hepatol; 2022; 12(3):745-754. PubMed ID: 35677519
[TBL] [Abstract][Full Text] [Related]
16. Degradable starch microspheres versus ethiodol and doxorubicin in transarterial chemoembolization of hepatocellular carcinoma.
Niessen C; Unterpaintner E; Goessmann H; Schlitt HJ; Mueller-Schilling M; Wohlgemuth WA; Stroszczynski C; Wiggermann P
J Vasc Interv Radiol; 2014 Feb; 25(2):240-7. PubMed ID: 24291001
[TBL] [Abstract][Full Text] [Related]
17. Validation and prognostic value of EZ-ALBI score in patients with intermediate-stage hepatocellular carcinoma treated with trans-arterial chemoembolization.
Ananchuensook P; Sriphoosanaphan S; Suksawatamnauy S; Siripon N; Pinjaroen N; Geratikornsupuk N; Kerr SJ; Thanapirom K; Komolmit P
BMC Gastroenterol; 2022 Jun; 22(1):295. PubMed ID: 35701739
[TBL] [Abstract][Full Text] [Related]
18. Transarterial chemoembolization with gelatin sponge microparticles for barcelona clinic liver cancer Stage C and large hepatocellular carcinoma: Initial clinical experience.
Zhou J; Liu Y; Ren Z; Zhang Y; Zhang M
J Cancer Res Ther; 2017; 13(5):767-772. PubMed ID: 29237901
[TBL] [Abstract][Full Text] [Related]
19. Safety and Efficacy of Selective Internal Radionuclide Therapy with
Bellendorf A; Mader N; Mueller SP; Ezziddin S; Bockisch A; Grafe H; Best J; Goebel J; Pöppel TD; Sabet A
Pharmaceuticals (Basel); 2024 Jan; 17(1):. PubMed ID: 38256934
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of two different transarterial chemoembolization protocols using Lipiodol and degradable starch microspheres in therapy of hepatocellular carcinoma: a prospective trial.
Vogl TJ; Langenbach MC; Hammerstingl R; Albrecht MH; Chatterjee AR; Gruber-Rouh T
Hepatol Int; 2021 Jun; 15(3):685-694. PubMed ID: 34043158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]